Jim Cramer's top 10 things to watch in the stock market Wednesday

Wholesale inflation fell 0.3% m/m in June (vs flat expectations), adding to a softer inflation backdrop alongside yesterday’s CPI. ASML rallied more than 3% after a blowout quarter and a second full-year guidance hike, while IBM sank 25% on an Oppenheimer downgrade to hold after missed estimates. Stripe and Advent International reportedly made a joint bid for PayPal at $60.50/share (valuing it at $53B+), which—if confirmed—could accelerate fintech consolidation.

Analysis

The softer inflation tape is less a macro growth signal than a duration signal: it lowers the equity risk premium and helps the market pay up for cash flows with visible compounding. That favors BLK more cleanly than the big money-center banks because fee revenue scales with AUM while cost discipline is already in place; it also supports semis/ASML by keeping multiples intact even if end-demand is merely stable. The flip side is that lower nominal growth can quietly pressure loan growth and credit-card spend later this year, so BAC and WFC may struggle to extend the good earnings headline into a cleaner 2H revenue story.

ASML’s strength is a reminder that the AI buildout is still bottlenecked by upstream equipment, not by downstream software narratives. The second-order loser is legacy IT spend: IBM’s miss is probably not an isolated execution problem but evidence that CIO budgets are still being reallocated toward compute, memory, and tools that directly support AI deployment. If that budget shift persists for 1-3 quarters, it is a structural multiple headwind for slower-growth enterprise software and a support for the capex winners.

The fintech M&A rumor around PYPL is interesting mostly because it validates how compressed standalone payment valuations have become, but the market is likely overpricing an immediate close. A sponsor-plus-platform structure could work, yet regulatory, financing, and diligence hurdles make this a months-long process at best; until there is a filing or confirmed strategic review, the trade is more volatility than fundamental rerating. JNJ looks like a cleaner dip-buy than the headline suggests, but only if the device weakness proves transitory on the next update; otherwise the market will keep discounting pharma durability against slower medtech growth.

Key Decisions for Investors

• Long BLK on intraday weakness or over the next 1-2 sessions; use lower-rate expectations as a 1-3 month tailwind. Risk/reward improves if equity markets stay firm and flows remain strong; falsify if AUM inflows slow or market breadth rolls over.
• Initiate a pair trade: long ASML / short IBM over 1-3 months. Thesis is capex rotation toward AI hardware and EUV capacity versus secular share loss in legacy enterprise spending. Cover the short if IBM guides back to growth or ASML orders decelerate.
• Sell rallies in IBM rather than buy the dip; prefer a tactical short only after any reflex bounce. This is a 2-6 week trade with downside if the market keeps punishing weak corporate IT spend; stop if next earnings preview shows stabilizing bookings.
• Treat PYPL as an event-driven watch item, not a conviction long, until a real transaction process is confirmed. If shares spike on rumor alone, fade part of the move with a tight stop; if a filed bid emerges, re-evaluate for 15-20% upside from current levels.
• Add JNJ only on post-earnings stabilization, not immediately into weakness. The catalyst path is 1-2 quarters; the thesis breaks if medical-device growth stays soft in the next print.